Value Sense
ABBV
AbbVie Inc. (ABBV)
Last Price$213.6(1.4%)
Market Cap$375.8B
LTM PEG 1Y
0.1x
5Y avg
0.1x
Drug Manufacturers - General industry median
0.2x
Stock quality & Intrinsic value
6/10
0.4% undervalued
ABBV
is 41.6% undervalued
learn more -->
50+
undervalued stocks
Start beating the S&P 500

AbbVie Inc. PEG 1Y

Annual
Quarterly
Daily
Crunching data... Almost there!
Dec'12Dec'13Dec'14Dec'15Dec'16Dec'17Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23Dec'24
PEG 1Y
0.0x
0.0x
0.1x
0.1x
0.0x
0.1x
0.0x
0.1x
0.1x
0.1x
0.1x
0.1x
0.1x
ABBV
Key metrics and insights to make informed decisions.
View full analysis
Overvalued or undervalued?
Check the intrinsic value for ABBV and see if it's the right time to invest.
Dive in

AbbVie Inc. (ABBV) PEG 1Y comparison analysis

General

LTM PEG 1Y

OTHER METRICS

Company name

Revenue growth

EPS growth

Net Income margin

AbbVie Inc. logo
AbbVie Inc.ABBV
0.2x
3.7%
(11.4%)
7.6%
Median Peer Set
0.3x
9.8%
11.0%
14.4%
Novo Nordisk A/S logo
Novo Nordisk A/SNVO
1.0x
24.9%
142.8%
34.8%
Eli Lilly and Company logo
Eli Lilly and CompanyLLY
0.7x
32.0%
102.4%
23.5%
Novartis AG logo
Novartis AGNVS
0.5x
10.8%
(16.5%)
23.1%
Merck & Co., Inc. logo
Merck & Co., Inc.MRK
0.4x
6.7%
4,714.3%
26.7%
Johnson & Johnson logo
Johnson & JohnsonJNJ
0.3x
4.3%
(57.9%)
15.8%
Amgen Inc. logo
Amgen Inc.AMGN
0.2x
18.6%
(39.8%)
12.2%
Pfizer Inc. logo
Pfizer Inc.PFE
0.2x
8.8%
273.7%
12.6%
Gilead Sciences, Inc. logo
Gilead Sciences, Inc.GILD
0.1x
6.0%
(91.6%)
1.7%
Sanofi logo
SanofiSNY
(5.0x)
(3.8%)
3.1%
12.6%
AstraZeneca PLC logo
AstraZeneca PLCAZN
(41.9x)
18.0%
18.9%
13.0%

ABBV key stats

USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
Dec'09Dec'10Dec'11Dec'12Dec'13Dec'14Dec'15Dec'16Dec'17Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23Dec'24
Revenue
% growth
14,214.2
0.0%
15,638.0
10.0%
17,444.0
11.5%
18,380.0
5.4%
18,790.0
2.2%
19,960.0
6.2%
22,859.0
14.5%
25,638.0
12.2%
28,216.0
10.1%
32,753.0
16.1%
33,266.0
1.6%
45,804.0
37.7%
56,197.0
22.7%
58,054.0
3.3%
54,318.0
(6.4%)
56,334.0
3.7%
Cost of Goods Sold (COGS)4,056.44,293.04,639.44,508.04,581.04,426.04,500.05,833.07,040.07,718.07,439.015,387.017,446.017,414.020,415.016,904.0
Gross Profit
% margin
10,157.8
71.5%
11,345.0
72.5%
12,804.6
73.4%
13,872.0
75.5%
14,209.0
75.6%
15,534.0
77.8%
18,359.0
80.3%
19,805.0
77.2%
21,176.0
75.0%
25,035.0
76.4%
25,827.0
77.6%
30,417.0
66.4%
38,751.0
69.0%
40,640.0
70.0%
33,903.0
62.4%
39,430.0
70.0%
Operating Expenses5,056.06,315.08,511.37,767.08,207.011,771.010,672.010,221.011,257.018,228.012,459.017,856.019,865.021,826.021,146.030,293.0
Research & Development Expenses (R&D)1,707.42,495.02,617.52,778.02,855.03,297.04,285.04,366.04,982.010,329.06,407.06,557.07,084.06,510.08,453.012,791.0
Selling, General & Administrative Expenses (SG&A)3,348.63,820.05,893.84,989.05,352.07,724.06,387.05,855.06,275.07,399.06,942.011,299.012,349.015,260.012,872.014,752.0
Operating Income
% margin
4,931.8
34.7%
4,717.0
30.2%
3,620.7
20.8%
6,622.0
36.0%
5,664.0
30.1%
3,411.0
17.1%
7,537.0
33.0%
9,340.0
36.4%
9,545.0
33.8%
6,383.0
19.5%
12,983.0
39.0%
11,363.0
24.8%
17,924.0
31.9%
18,117.0
31.2%
12,757.0
23.5%
9,137.0
16.2%
Interest Income0.028.020.020.021.038.033.082.0146.0204.0275.0174.039.0186.0540.0648.0
Interest Expense0.00.00.0104.0299.0429.0719.01,047.01,150.01,348.01,784.02,454.02,423.02,230.02,224.02,808.0
Pre-tax Income5,950.34,836.03,668.55,725.05,332.02,369.06,645.07,884.07,727.05,197.08,426.03,398.012,989.013,477.06,250.03,716.0
Income Tax
% effective tax rate
1,313.8
22.1%
658.0
13.6%
235.4
6.4%
450.0
7.9%
1,204.0
22.6%
595.0
25.1%
1,501.0
22.6%
1,931.0
24.5%
2,418.0
31.3%
490.0
9.4%
544.0
6.5%
1,224.0
36.0%
1,440.0
11.1%
1,632.0
12.1%
1,377.0
22.0%
(570.0)
(15.3%)
Net Income
% margin
4,636.5
32.6%
4,178.0
26.7%
3,433.1
19.7%
5,275.0
28.7%
4,128.0
22.0%
1,774.0
8.9%
5,144.0
22.5%
5,953.0
23.2%
5,309.0
18.8%
5,687.0
17.4%
7,882.0
23.7%
4,616.0
10.1%
11,542.0
20.5%
11,836.0
20.4%
4,863.0
9.0%
4,278.0
7.6%
EPS2.872.592.123.352.581.113.153.653.313.695.302.736.486.652.732.42
Diluted EPS2.852.572.113.352.561.103.133.633.303.685.282.726.456.632.722.41
EBITDA
% margin
6,647.8
46.8%
6,020.0
38.5%
4,940.7
28.3%
6,979.0
38.0%
6,914.0
36.8%
6,286.0
31.5%
9,692.0
42.4%
10,812.0
42.2%
11,774.0
41.7%
13,688.0
41.8%
16,264.0
48.9%
21,148.0
46.2%
28,280.0
50.3%
31,424.0
54.1%
17,308.0
31.9%
14,910.0
26.5%

Discover more Stock Ideas

Undervalued stocks right now

Undervalued stocks right now

Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.

3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Undervalued growth stocks

Undervalued growth stocks

Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.

3M Return 35.3%
S&P Outperformance 22.3%
Next 3M Predicted Return 26.8%
Undervalued dividend stocks

Undervalued dividend stocks

Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.

3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
More ideas -->

FAQ

1) What is AbbVie Inc.'s PEG 1Y?

As of today, Microsoft Corp's last 12-month PEG 1Y is 0.1x, based on the financial report for Dec 30, 2024 (Q4’2024). The average annual PEG 1Y for AbbVie Inc. have been 0.1x over the past three years, and 0.1x over the past five years.

2) Is AbbVie Inc.'s PEG 1Y Good?

As of today, AbbVie Inc.'s PEG 1Y is 0.1x, which is lower than industry median of 0.2x. It indicates that AbbVie Inc.'s PEG 1Y is Good.

3) How does AbbVie Inc.'s PEG 1Y compare to its peers?

As of today, AbbVie Inc.'s PEG 1Y is 0.1x, which is lower than peer median of 0.3x. The list of peers includes NVO, LLY, NVS, MRK, JNJ, AMGN, PFE, GILD, SNY, AZN.